Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Julphar
Mallinckrodt
Cantor Fitzgerald
McKesson
AstraZeneca
Federal Trade Commission
Healthtrust
Chubb

Generated: November 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 210259

« Back to Dashboard

NDA 210259 describes CALQUENCE, which is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the CALQUENCE profile page.

The generic ingredient in CALQUENCE is acalabrutinib. One supplier is listed for this compound. Additional details are available on the acalabrutinib profile page.
Summary for 210259
Tradename:CALQUENCE
Applicant:Astrazeneca
Ingredient:acalabrutinib
Patents:4
Generic Entry Opportunity Date for 210259
Generic Entry Date for 210259*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 210259
Mechanism of ActionTyrosine Kinase Inhibitors
Suppliers and Packaging for NDA: 210259
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CALQUENCE acalabrutinib CAPSULE;ORAL 210259 NDA AstraZeneca Pharmaceuticals LP 0310-0512 0310-0512-28 28 CAPSULE, GELATIN COATED in 1 BOTTLE (0310-0512-28)
CALQUENCE acalabrutinib CAPSULE;ORAL 210259 NDA AstraZeneca Pharmaceuticals LP 0310-0512 0310-0512-60 60 CAPSULE, GELATIN COATED in 1 BOTTLE (0310-0512-60)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength100MG
Approval Date:Oct 31, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 31, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Oct 31, 2024
Regulatory Exclusivity Use:TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
Patent:➤ Sign UpPatent Expiration:Nov 24, 2026Product Flag?Substance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Baxter
Fish and Richardson
McKinsey
Accenture
Citi
Federal Trade Commission
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.